Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 26 Mar 2019 |
| Genmab Announces European Regulatory Submission for Daratumumab in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma | 22 Mar 2019 |
| Genmab Announces Appointment of Marisol Peron as Head of Communications and Investor Relations | 11 Mar 2019 |
| Genmab A/S has published its Articles of Association | 8 Mar 2019 |
| Grant of Restricted Stock Units and Warrants to Employees in Genmab | 1 Mar 2019 |
| Genmab A/S Summons Annual General Meeting | 28 Feb 2019 |